Male-pattern baldness of moderate intensity in men.warning: in women, the use of minoxidil is not recommended due to the limited efficacy and high incidence (in 37% of cases) of excessive hair outside the application areas.
Composition:
1 ml of the solution contains 50 mg minoxidil.
Action:
Minoxidil stimulates the growth of keratinocytes and hair growth in a group of patients with androgenetic alopecia. After topical administration, an average of 1.7% of the dose used is given to the systemic circulation. After discontinuation of topical administration, approximately 95% of absorbed minoxidil is excreted within 4 days.
Contraindications:
Hypersensitivity to the active substance or to any of the excipients. Lesions or traumas of the scalp. Poor tolerability of the drug at a concentration of 2%, regardless of the symptoms.
Precautions:
In patients with dermatitis of the scalp, increased percutaneous absorption of minoxidil is possible. When using the solution, caution should be exercised and regular monitoring of symptoms suggestive of systemic effects such as: reduction of blood pressure, tachycardia, signs of water retention or sodium in the body. Particularly cautiously use in patients with cardiovascular disease or cardiac dysfunction (risk of tachycardia, water or sodium retention in the body or weight gain). At the beginning of treatment and regularly during therapy, the patient should be observed. Treatment should be discontinued if systemic effects or severe skin reactions occur. Minoxidil is not indicated in people with a history of hair loss, sudden and / or partial hair loss, hair loss is a result of childbirth or the cause of hair loss is unknown. Discontinue use in the event of: hypotension, chest pain, rapid heartbeat, fainting or dizziness, sudden unexplained weight gain, swollen hands or feet or permanent redness or irritation of the scalp. Minoxidil should only be used on normal healthy scalp. Do not use when the scalp is red, there is inflammation, infection, irritation or pain and when other medicines are applied to the scalp. In the event of contact with eyes, the solution (especially due to the ethanol content) can cause burning sensation and irritation. Accidental ingestion of the solution may cause serious side effects. It is not recommended to be in the sun when using the medicine. Due to the lack of data on efficacy and safety, the use in children and adolescents <18 years and in patients> 65 years is not recommended
Pregnancy and lactation:
It is not recommended for women.
Side effects:
Very common: headaches, excessive hairiness (outside the place of application). Common: depression, dyspnoea, contact dermatitis (due to the presence of propylene glycol), pruritis, skin inflammation, rash, acne-prone form, musculoskeletal pain, local reactions at the site of administration (irritation, scaling of the skin, dermatitis, erythema, dry skin, pruritus, peripheral edema, pain). Not known: ear infection, otitis externa, rhinitis, hypersensitivity, neuritis, tingling sensation, taste disturbances, burning sensation, blurred vision, eye irritation, dizziness, tachycardia, chest pain, palpitations, hypotension, hepatitis , generalized erythema, baldness, uneven body hair, change of hair texture, change of hair color, kidney stones, swelling of the face, swelling, asthenia. Due to the ethanol content, frequent use on the skin may cause irritation and dry skin.
Dosage:
Outwardly. Adults: Apply 1 ml of the solution to the scalp, starting from the center of the treated area, twice a day. This dosage should be used regardless of the size of the surface being treated. Do not exceed the dose of 2 ml of solution per day.Hair and scalp should be completely dry before using the medicine. Do not use on another part of the body. To stimulate hair growth, you may need treatment for 2 months. In younger patients who have been bald for a short period of time or whose baldness affects small areas of the skin at the apex of the head there is a high probability that they will respond well to treatment. Return to the initial state can be observed after 3 or 4 months after discontinuation of the drug.
(C)
